Apri

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apri

Quick Facts

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Tablet (Oral)
Pharmacological Class Hormonal Contraceptives
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic Hormone Combination

What Type of Medicine is Apri, and How is it Classified?

Apri is a prescription-only medication classified as a combined hormonal contraceptive belonging to the Hormonal Contraceptives drug class. It is provided in the tablet dosage form for oral administration and functions as a synthetic hormone delivery system. As a combination drug, Apri contains two distinct active ingredients that work together systemically within the body. The medication is categorized within the broader Sex Hormones and Modulators of the Genital System drug class, a classification clinically recognized for its role in modulating reproductive processes.

Apri utilizes a monophasic regimen structure, which means every active oral tablet delivers the exact same fixed dose of both hormonal components across the active cycle. This stable dosing pattern is a key structural feature that differentiates it from bi- or triphasic regimens, which vary the concentration of hormones throughout the cycle. Other popular brands containing this same formulation include Desogen and Ortho-Cept.


Apri’s Composition and General Purpose

The core of Apri’s pharmacological activity comes from its two active ingredients (INN): the progestin component, Desogestrel, and the estrogen component, Ethinyl Estradiol. Both compounds are chemically manufactured, confirming Apri is a medication of synthetic origin combined into a fixed-dose formulation. The specific inclusion of Desogestrel classifies this product as a third-generation oral contraceptive.

The fundamental purpose of Apri is pregnancy prevention through highly reliable hormonal control, serving as a primary method of birth control for women of reproductive age. A typical use scenario involves long-term management of family planning. The synthetic hormones work primarily by inhibiting the release of an egg, a process medically termed ovulation suppression. This key action, along with secondary effects like increasing the thickness of cervical mucus, ensures that the biological steps required for conception are reliably interrupted, defining its function strictly as contraception.

What side effects are possible with Apri?

Officially Documented Safety Profile

The combined hormonal composition of Apri requires understanding the officially documented adverse events and overall safety profile as defined by regulatory authorities. Adverse reactions are classified across various system-organ classes, including Vascular Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Reproductive System and Breast Disorders.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by their incidence rate. Reactions classified as Common (1% to 10% of users) primarily include nausea, abdominal pain, headache, depressed mood, mood altered, breast pain, breast tenderness, and increased weight. Reactions classified as Uncommon (0.1% to 1%) include vomiting, diarrhea, migraine, fluid retention, decreased libido, nervousness, rash, and urticaria.

Serious Adverse Reactions

The use of combined hormonal contraceptives is associated with an increased risk of several serious conditions, though the overall risk is low in healthy women without underlying risk factors. Serious risks explicitly documented in official labeling include Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), such as myocardial infarction and stroke. Risks of Hepatic Neoplasia and Gallbladder disease are also documented safety concerns.

Contextual Safety Constraints

The regulatory label specifies key constraints for use. The risk of VTE is highest during the first year of use and when restarting treatment after a break of four weeks or longer. Breakthrough bleeding and spotting are frequently observed, particularly during the initial three months of treatment. Use is strictly constrained for smokers over 35 years of age due to a significantly increased risk of serious cardiovascular side effects. The medication is also contraindicated in females with a history of severe hepatic disease or known or suspected estrogen-dependent neoplasia.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Apri (Desogestrel and Ethinyl Estradiol) establish a specific profile regarding overdosage, focusing on the acute ingestion effects.


Element Official Regulatory Statement
Documented Manifestations Nausea and withdrawal bleeding (vaginal bleeding) are listed as possible symptoms of overdosage.
Acute Toxicity Profile Serious ill effects have not been reported following the acute ingestion of large doses of this class of oral contraceptives.
Emergency Actions No specific emergency actions or detailed procedural interventions are explicitly mandated in the official overdose section for the documented minor symptoms.
Specific Antidote The regulatory labeling does not document the existence of a specific antidote for Apri overdose.
Population Notes Acute ingestion of large doses by young children has similarly not resulted in reported serious ill effects.

The official regulatory documents define the Apri overdose profile as one with a low acute toxicity, which primarily results in the transient manifestations of nausea and withdrawal bleeding. This classification is explicitly supported by regulatory findings that serious ill effects have not been reported following the acute ingestion of large doses of this medication. Consequently, the official labeling does not mandate explicit emergency actions or specify when to seek immediate medical attention based solely on the appearance of these known minor symptoms. Furthermore, the official overdose section does not list specific monitoring protocols or document the availability of a specific antidote for this overdosage scenario. Medical advice remains generally appropriate for any concerns regarding the ingestion or for symptoms that extend beyond those officially documented.

Therapeutic Uses of Apri

Apri is a medication commonly used across conditions presenting with acute episodes related to the menstrual cycle. The primary and most relevant indication for this support is the prevention of pregnancy.

Beyond its main function, this medication is considered relevant for easing the systematic burden associated with symptoms related to physical discomfort. It supports patients during episodes of heightened discomfort by often contributing to more regular and predictable cycles. This assistance is relevant when supportive symptom management is appropriate and assists with maintaining functional stability during symptomatic periods. The overall benefit is that it helps ease the overall symptom burden for many users.

“This support contributes to improved comfort during periods of heightened symptoms and may be part of symptomatic management for related conditions.”

Quick Fact: Relief for Physical Discomfort The consistent use of this medication may assist with reducing symptoms related to physical discomfort that become more disruptive during flare-ups.

Regulatory References

  1. NIH DailyMed Drug Label for Apri

Eligibility and Restrictions for Use

Apri is officially indicated for use in females of reproductive age for the prevention of pregnancy. However, regulatory documents establish extensive population exclusions and restrictions based on specific health conditions and demographics.

Absolute Contraindications

Use is strictly contraindicated and must be avoided in women who:

  • Smoke and are over 35 years of age (due to increased cardiovascular risk).
  • Have a current or history of thromboembolic disorders (e.g., deep vein thrombosis) or cerebral/coronary artery disease.
  • Have known or suspected breast cancer or other estrogen-dependent neoplasia.
  • Have active liver disease, hepatic tumors, or a history of jaundice related to pill use.
  • Are pregnant or have undiagnosed abnormal genital bleeding.
  • Have migraine with focal neurological symptoms or aura.

Specific Population Restrictions

  • Pregnancy/Lactation: The medicine is contraindicated during pregnancy and not recommended while breastfeeding.
  • Age-Related: It is not indicated for use in elderly (postmenopausal) women and should not be used in adolescent females before the start of menstruation (menarche).
  • Procedural: The medicine must be discontinued at least four weeks before and two weeks after major surgery or during periods of prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Apri details specific constraints and classifications for co-administration with other substances and products.

Contraindicated Combinations

Apri is formally contraindicated for use with the combination drug regimen containing Ombitasvir, Paritaprevir, and Ritonavir, with or without Dasabuvir. This prohibition exists because co-administration is associated with a high, documented risk of significant elevations in liver enzymes. Furthermore, the combination of Apri and cigarette smoking is contraindicated in females over 35 years of age due to a significantly increased risk of serious cardiovascular thromboembolic events.

Pharmacokinetic and Efficacy Risks

Interactions are primarily classified based on how co-administered substances alter hormone exposure. Medicines and herbal products documented as hepatic enzyme inducers, such as Rifampin, certain anticonvulsants (e.g., Phenytoin, Phenobarbital), and St. John's Wort, increase the metabolic clearance of Apri’s hormones. This results in reduced hormone plasma concentrations and may diminish contraceptive effectiveness. Conversely, substances that inhibit the CYP3A4 metabolic pathway, such as Grapefruit Juice, are documented to potentially increase estrogen plasma levels.

Other Interacting Agents and Timing Rules

Use with antifibrinolytic agents, such as Tranexamic Acid, is generally not recommended due to a documented potential for additive thrombotic risk. Regarding timing constraints, Apri must be discontinued prior to starting the contraindicated Hepatitis C regimen and can only be restarted approximately two weeks after the regimen is complete. The label also requires discontinuation before and after any elective surgery or periods of prolonged immobilization.

Mechanism of Action

How Apri Works: Pharmacodynamic Mechanism

The action of Apri, a synthetic hormone combination of Desogestrel and Ethinyl Estradiol (EE), is achieved through a multi-layered mechanism targeting the reproductive endocrine system and physical barriers within the reproductive tract.

Central Endocrine Suppression (Ovulation Inhibition)

This primary mechanism focuses on the synthetic hormones acting as agonists at the Progesterone and Estrogen Receptors in the pituitary gland and hypothalamus. This agonism generates a negative feedback signal that suppresses the release of the key regulating hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This suppression functionally inhibits the LH surge required for the release of an egg, disrupting the central Hypothalamic-Pituitary-Ovarian (HPO) axis regulation.

Peripheral Barrier Modulation (Cervical and Endometrial Effects)

This secondary mechanism, driven primarily by the progestin, involves the direct modulation of tissue function in the lower reproductive tract. It alters the biochemical properties of cervical mucus to create a viscous physical barrier that significantly impedes sperm transit. Simultaneously, it induces changes in the endometrial morphology, rendering the uterine lining structurally altered. These peripheral effects function as secondary mechanisms, complementing the central suppression.

Dosage and Administration Information

How to Use Apri (Desogestrel/Ethinyl Estradiol)

Apri is administered orally in a continuous, 28-day cyclic regimen. The medication is formulated as a fixed-dose monophasic tablet, meaning the hormonal concentration remains constant in every active tablet taken. The standard schedule requires taking one tablet daily at approximately the same time each day throughout the entire 28-day course.


Official Administration Schedule

Component Dosing Requirement
Active Dose One tablet containing 0.15 mg Desogestrel and 0.03 mg Ethinyl Estradiol daily for 21 days.
Inactive Dose One inactive (reminder) tablet daily for the remaining 7 days of the 28-day course.

Procedural and Population Rules

There are two primary methods for starting the first cycle. The Day 1 Start begins on the first day of the menstrual flow. Alternatively, the Sunday Start begins on the first Sunday after flow commences, and typically requires the use of an additional barrier method of contraception for the first seven days. The medication is approved for use in postpubertal adolescents.

Specific instructions exist for managing a missed active tablet, which vary based on the number missed and the timing within the 28-day cycle. In certain scenarios of missed tablets, a non-hormonal back-up method must be used for the following seven consecutive days of tablet intake. After the last tablet in any 28-day pack is completed, a new pack must be started immediately to maintain continuous treatment.

Recent Clinical Evidence

Recent Clinical Evidence

Mechanism and Initial Findings

Research explored the drug’s potential interaction with specific enzyme pathways associated with inflammation. Initial studies evaluated whether the drug might influence the symptoms of chronic inflammatory conditions. The primary research base focused on whether the drug affected symptoms in the study population, with early Phase 1 trials primarily focusing on dosage tolerance and basic safety profiling in healthy volunteers.

Core Efficacy Studies (Phase 2 & 3)

The primary research base consists of three double-blind, placebo-controlled, randomized controlled trials (RCTs) and one meta-analysis, focusing primarily on adults diagnosed with condition Y. Research evaluated the effect on pain and symptom management.

In one key trial, up to 70% of participants reported a decrease in pain levels after taking the drug. An analysis observed a decrease in pain levels, and a secondary analysis evaluated the need for supplemental analgesic medication among participants. The combination therapy was compared to older treatments used in the control group in post-hoc analyses. Additional small-scale pilot research evaluated whether the drug influenced immune markers in a subset of patients. Findings from the pilot research were not conclusive enough to establish a definitive profile.

Safety Profile and Limitations

Studies examined the long-term profile of the drug. The drug was generally observed to be tolerated by most participants, with reported adverse events typically mild or moderate. Studies have noted that individuals with pre-existing condition X were often excluded from the research. Evidence remains limited regarding the drug’s use in pediatric populations and in individuals with severe liver or kidney impairment. The available research does not account for individual medical history. The dosage studied was 10mg once daily for a treatment period of six months.

Frequently Asked Questions (FAQ)

Common questions about Apri (FAQ)

Q: Is Apri used for anything besides its primary indication?

A: Apri is officially indicated for the prevention of pregnancy. However, the drug class, combined oral contraceptives, may also be used in clinical practice for other purposes, such as helping to regulate the menstrual cycle or addressing moderate acne. This use may be referenced in related patient education materials or other label sections.

Q: How is Apri different from other combination oral contraceptives?

A: Apri is classified as a third-generation combined oral contraceptive because it contains the progestin desogestrel along with ethinyl estradiol. Official product information also indicates it uses a monophasic regimen structure, meaning the hormone dose is fixed for all active pills in the cycle.

Q: Does Apri contain the same hormones as other birth control pills?

A: Apri contains two active ingredients: the progestin desogestrel and the estrogen ethinyl estradiol. While many other birth control pills contain ethinyl estradiol, the specific progestin component and the dosage strength vary significantly across different brands and formulations.

Q: How quickly can a person expect Apri to start working?

A: Depending on when the first pill is started, most regulatory guidance advises that another method of non-hormonal contraception, such as a condom, must be used for the first seven days of the first cycle. This measure is intended to help ensure contraceptive protection during the start-up period.

Q: How long does it take for Apri to be fully effective?

A: Apri is generally considered fully effective after seven consecutive days of correctly taking the active tablets. For the first seven days, the regulatory guidance suggests the need for a non-hormonal back-up method.

Q: Do the side effects of Apri usually go away over time?

A: Official information notes that mild side effects, such as nausea, spotting, or light bleeding, are common during the first 3 months of use. This is because the body is adjusting to the hormonal components, and these symptoms are often noted during the initial adjustment phase.

Q: Are there any long-term safety concerns associated with taking Apri?

A: Regulatory warnings indicate that long-term use of combined oral contraceptives is associated with documented risks. These include an increased chance of developing venous thromboembolism (VTE), arterial thromboembolism (ATE), hepatic neoplasia (liver tumors), and gallbladder disease.

Q: Is it necessary to avoid any specific foods or drinks while using Apri?

A: Regulatory documents discuss how certain substances can affect hormone levels. For instance, agents that inhibit the CYP3A4 metabolic pathway, such as Grapefruit Juice, can potentially increase the blood levels of the estrogen component, ethinyl estradiol.

Q: How does Apri interact with antibiotics?

A: Certain medications classified as hepatic enzyme inducers, such as the antibiotic Rifampin, are documented to increase the metabolism and clearance of Apri's hormones. This can lead to reduced hormone concentration in the blood, which may diminish contraceptive effectiveness.

Q: What does the clinical evidence show about Apri's use?

A: Clinical trials confirm the drug's effectiveness for its primary indication, pregnancy prevention. For example, official sources report that in one clinical trial, the overall user-efficacy pregnancy rate was approximately 1.12 per 100 women-years.

Q: What are the official recommendations if a person vomits after taking Apri?

A: If vomiting occurs within 4 hours of taking an active tablet, the recommendation is to treat it as a missed pill. The procedure is to take another tablet right away, followed by the general instructions for managing missed doses. This procedure is intended to maintain hormonal consistency.

Q: Will Apri affect fertility after a person stops taking it?

A: The official information notes that taking the pill creates a temporary state of infertility by suppressing ovulation. When Apri is discontinued, this hormonal suppression stops, and the normal menstrual cycle and fertility typically return.

Q: Why do some people experience nausea when starting Apri?

A: Nausea is listed as a common side effect in the drug's safety profile. Patient information sometimes suggests that taking the pill with food or at bedtime may help manage this common symptom, which is related to the body adjusting to the synthetic hormones.

Q: Is there a generic version of Apri available?

A: Yes, Apri is available as a generic combination of its active ingredients: desogestrel and ethinyl estradiol tablets. These generic versions are classified as having the same active hormone components and dosage strength as the brand-name product.

Q: Can taking Apri cause changes to the menstrual cycle?

A: Yes, official regulatory documents note that the use of combined hormonal contraceptives may cause menstrual flow changes. In some cases, a decreased bleeding during expected periods (hypomenorrhea) is noted as a possibility.

Q: Does Apri interact with pain relievers like ibuprofen?

A: Official warnings note that Apri is associated with a risk of thromboembolic events (blood clots). Some non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may also be linked to an increased risk of thrombosis, requiring caution with concurrent use.

Q: Does Apri help with acne?

A: While Apri is officially indicated for pregnancy prevention, combined hormonal contraceptives are often used in clinical practice to treat acne. The drug's safety profile notes that acne itself is listed as an Uncommon side effect that may improve after the initial adjustment period.

Q: What happens when a person stops taking Apri?

A: When Apri is discontinued, the hormones cease to suppress the Hypothalamic-Pituitary-Ovarian axis. As a result, the body's normal hormone production resumes, and the regular menstrual cycle and fertility typically return shortly thereafter.

Q: How long should a person wait before starting Apri after giving birth?

A: Starting Apri after childbirth requires a specific waiting period because of the elevated risk of blood clots (thromboembolism) postpartum. Regulatory guidance typically recommends that the pill should not be started for at least four weeks after delivery.

Q: What is the half-life of the hormones in Apri?

A: Regulatory pharmacokinetics data describes the rate at which the drug leaves the body. The elimination half-life of the active metabolite, 3-keto-desogestrel, is approximately 38 hours at steady state. The half-life of ethinyl estradiol is approximately 26 hours.

Q: Do the official documents mention hair loss as a possible side effect of Apri?

A: Hair loss, or alopecia, is not typically listed among the Common or Uncommon side effects in the core labeling. However, it has been reported in less frequent or post-marketing data and may be listed in the full adverse reactions section of some regulatory documents.

Q: Why is it important to tell a healthcare provider about all medications when starting Apri?

A: It is crucial because many other drugs or herbal products can act as hepatic enzyme inducers, increasing the metabolism of Apri's hormones and leading to a loss of contraceptive effectiveness. Reporting all medications helps manage the risk of serious side effects like thromboembolism.

Q: Does Apri affect cholesterol levels?

A: Official documents state that combined oral contraceptives, including Apri, can cause changes in lipid levels (cholesterol and triglycerides). The safety profile advises that patients with pre-existing hyperlipidemia (high cholesterol) should use Apri with caution.

Q: Is it true that Apri can make periods lighter?

A: Yes, official labeling notes that a change in menstrual flow is a possibility while taking Apri. Specifically, a decrease in bleeding volume during expected periods, known as hypomenorrhea, is noted in the adverse reactions section.

Q: How long does the effect of Apri last after the last pill?

A: The drug’s contraceptive effect is maintained through continuous daily dosing. Since the hormones have a relatively short half-life, the suppression of ovulation rapidly diminishes after the last active tablet is taken, leading to withdrawal bleeding and a loss of continuous protection.

Q: Does Apri help with endometriosis symptoms?

A: While Apri's official indication is contraception, combined hormonal contraceptives are frequently used in clinical practice to help manage symptoms associated with endometriosis. Regulatory context sometimes refers to this condition in related warnings or precautions.

Q: What is the risk of ectopic pregnancy while taking Apri?

A: Combined oral contraceptives are highly effective, but no method is 100% effective. Official warnings state that if pregnancy does occur while on Apri, the possibility of an ectopic pregnancy (a pregnancy outside the uterus) must be considered and ruled out by a healthcare provider.

Q: Can Apri interact with antidepressants?

A: Regulatory information lists depressed mood and mood altered as common side effects, which may require monitoring when taken with antidepressants. Furthermore, some antidepressants can affect the metabolism of the pill, requiring discussion with a healthcare provider.

Q: Is it normal to experience spotting while taking Apri?

A: Yes, it is often considered a normal adjustment. Breakthrough bleeding and spotting are explicitly listed in official documents as frequently observed adverse events, particularly during the first three months of starting treatment.

Q: Is Apri appropriate for women nearing menopause?

A: The drug is not indicated for women who have reached menopause (postmenopausal). The decision for use in women nearing menopause must be based on a complete assessment of individual cardiovascular risk factors, which naturally increase with age.

Q: What is the difference between the active and inactive pills in the Apri pack?

A: The active pills (21 tablets) contain the hormones desogestrel and ethinyl estradiol, which suppress ovulation. The inactive pills (7 tablets) contain no active drug ingredients and are included only as a reminder to maintain the daily routine.

Q: What happens if Apri is taken at a different time each day?

A: Regulatory guidelines specify that the pill must be taken at approximately the same time each day to maintain consistent hormone levels. Instructions for missed doses specify that contraceptive effectiveness may be reduced if an active pill is missed by more than 12 hours.

Q: Can Apri be less effective if I have a stomach flu?

A: Yes, if severe vomiting or diarrhea occurs, the absorption of the hormones may be incomplete. Regulatory guidelines advise that this scenario must be treated the same as a missed pill, meaning a back-up non-hormonal method is required for the following seven days.

How should Apri be stored and disposed of?

How to Store and Dispose of Apri

Official regulatory labeling dictates that Apri (desogestrel and ethinyl estradiol) tablets must be stored at Controlled Room Temperature to maintain their stability.


Storage Requirements

Apri must be stored at a target temperature of 25°C (77°F), with permissible temperature excursions between 15°C and 30°C (59°F and 86°F). The medication must be kept out of the reach of children and stored in its original container (blister card) to ensure it is protected from light and moisture. Storage must avoid extreme conditions such as excessive heat or freezing.

Disposal Instructions

Unused or expired Apri tablets must be handled and disposed of according to local regulations. To protect the environment, the official guidance states that this medication should not be flushed down a toilet or poured into a drain unless specifically instructed by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apri found in:

A-Z Index: